Heska Corp (HSKA): Kevin S. Wilson , CEO and President of Heska Corp sold 3,779 shares on Jul 20, 2016. The Insider selling transaction was reported by the company on Jul 22, 2016 to the Securities and Exchange Commission. The shares were sold at $44.02 per share for a total value of $166,362.16 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 19, 2016, Kevin S. Wilson (CEO and President) sold 5,465 shares at $44.31 per share price.On Jul 11, 2016, Jason A Napolitano (COO, CFO, EVP and Secretary) sold 20,000 shares at $41.00 per share price.Also, On May 10, 2016, Sharon L. Riley (director) sold 5,000 shares at $36.87 per share price.On May 10, 2016, Michael J Mcginley (Presi, Biologic. & Pharm.) sold 5,998 shares at $36.50 per share price.
Heska Corp: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in Heska Corp which led to swings in the share price. The shares opened for trading at $43.18 and hit $44.4015 on the upside , eventually ending the session at $43.44, with a gain of 1.35% or 0.58 points. The heightened volatility saw the trading volume jump to 83,214 shares. The 52-week high of the share price is $44.99 and the company has a market cap of $290 M . The 52-week low of the share price is at $26.255.
Company has been under the radar of several Street Analysts.Heska Corp is Initiated by Sidoti to Buy. The Rating was issued on Jul 1, 2016.
Heska Corporation develops manufactures markets sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. The Company operates in two segments: Core Companion Animal Health and Other Vaccines Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes primarily for canine and feline use blood testing instruments and supplies digital imaging products software and services and single use products and services such as heartworm diagnostic tests heartworm preventive products allergy immunotherapy products and allergy testing. The Other Vaccines Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production primarily for cattle but also for other animals including small mammals.